Press Releases
May 30, 2024
BOSTON , May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences , Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief
May 8, 2024
BOSTON , May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences , Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision immunotherapies to treat solid tumors designed to preserve the function of the organ with cancer, today announced that Elisabet de los Pinos, PhD, Chief
February 26, 2024
BOSTON --(BUSINESS WIRE)--Feb. 26, 2024-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer,